VU0453379 (VU-0453379; VU 0453379) is a novel, CNS-penetrant and potent glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM) with EC50 of 1.3 μM.

Liraglutide, a Glucagon-like Peptide 1 (GLP-1) analog, is a potent agonist of the Glucagon-like Peptide 1 receptor.

L-168,049 (L 168,049; L168,049) is a novel, selective, orally bioactive and non-peptidyl antagonist of human glucagon receptor (GR) with anti-diabetic activity.

Glucagon receptor antagonists-1 is a novel and potent antagonist of glucagon receptors.

Glucagon receptor antagonists-3 is a novel and potent antagonist of glucagon receptors.

Glucagon receptor antagonists-2 is a glucagon receptor antagonist.

GLP-1 receptor agonist 2 is a novel and potent agonist of glucagon-like peptide-1 receptor (GLP-1R) with anti-diabetic activity.

Adomeglivant (formerly known as LY-2409021) is a novel, potent and selective glucagon receptor antagonist that is being investigated in clinical trial for type 2 diabetes mellitus.

Glucagon (19-29) [also known as Miniglucagon; Des(1-18) glucagon] is an endogenous short peptide acting as a regulator of the pancreatic islet physiology.

Tirzepatide (formerly known as LY3298176; trade name Mounjaro) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been approved by FDA in May 2022 for the treatment of type 2 diabetes.